drugset
Drugs / Luseogliflozin
last change Aug 2018 re-read 2 minutes ago

Luseogliflozin

also known as Luseogliflozina · Luseogliflozine · TS-071 · TS-71

Small molecule

Developed for
type 2 diabetes mellitus
Investigated by
Kansai Electric Power Hospital · Medical Corporation Heishinkai OCROM Clinic

Trials 1 · a red edge is where a trial was stopped

today NCT02500186 · not/applicable
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
— NCT02500186 May → Dec 2015 type 2 diabetes mellitus Kansai Electric Power Hospital Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT02528019 Comparator Aug 2015 → Aug 2017 — Kurume University Unknown No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as luseogliflozin “luseogliflozin (2.5-5mg)” NCT02528019 ↗
1

NCT02500186 ↗
Known as Luseogliflozina ChEMBL registry synonym — accepted as the source's own label CHEMBL1093423 ↗
Known as Luseogliflozine ChEMBL registry synonym — accepted as the source's own label CHEMBL1093423 ↗
Known as TS-071 ChEMBL registry synonym — accepted as the source's own label CHEMBL1093423 ↗
Known as TS-71 ChEMBL registry synonym — accepted as the source's own label CHEMBL1093423 ↗
Action Inhibit “which inhibits glucose reabsorption from renal uriniferous tubule” NCT02500186 ↗
Modality Small molecule — CHEMBL1093423 ↗
Route Oral “Study patients orally receive luseogliflozin 2.5 mg s.i.d. before breakfast” NCT02500186 ↗